Highlight
– Cascade genetic screening in ATTRv families identifies asymptomatic carriers who may develop disease earlier than predicted.
– Early diagnosis through screening correlates with improved survival compared to index cases.
– Disease-modifying therapies independently reduce mortality in ATTRv patients.
– Variant-specific follow-up protocols are critical due to variable penetrance and age of onset.
